The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk
Transforming growth factor-beta 1 (TGF-β1) is a potent inhibitor of proliferation of epithelial, endothelial and hematopoietic cells and acts as a tumor suppressor. The gene for TGF-β1, TGFB1, carries a common T/C variation of nucleotide 29, resulting in a leucine (L) to proline (P) polymorphism at...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2003-11, Vol.201 (2), p.181-184 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 184 |
|---|---|
| container_issue | 2 |
| container_start_page | 181 |
| container_title | Cancer letters |
| container_volume | 201 |
| creator | Krippl, Peter Langsenlehner, Uwe Renner, Wilfried Yazdani-Biuki, Babak Wolf, Gerald Wascher, Thomas C. Paulweber, Bernhard Bahadori, Babak Samonigg, Hellmut |
| description | Transforming growth factor-beta 1 (TGF-β1) is a potent inhibitor of proliferation of epithelial, endothelial and hematopoietic cells and acts as a tumor suppressor. The gene for TGF-β1, TGFB1, carries a common T/C variation of nucleotide 29, resulting in a leucine (L) to proline (P) polymorphism at codon 10 (TGFB1 L10P). The less common 10P allele has repeatedly been linked to higher TGF-β1 levels and in at least one study to a lower incidence of breast cancer. To further analyze the role of this polymorphism for breast cancer risk, 500 patients with histologically confirmed breast cancer and 500 sex-and age-matched healthy control subjects were genotyped for the TGFB1 L10P polymorphism by an allele-specific polymerase chain reaction assay. TGFB1 LL, LP and PP genotype frequencies were not significantly different for patients (39.6, 44.2, 16.2%) and controls (36.5, 45.9, 17.6%). We conclude that the TGFB1 L10P polymorphism is not associated with breast cancer risk. |
| doi_str_mv | 10.1016/S0304-3835(03)00468-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71377406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383503004683</els_id><sourcerecordid>19187299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-144200620625363372a758a8e35c4bc3cc24097c5455f0eb76ab08a744821fd93</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6E5SAKHporXSSTvdJZPELBhRczyGdrp7JOt2ZTWVc9t-b-cAFLwuBHPLUS-V9GHsu4J0A0bz_CRJUJVup34B8C6CatpIP2EK0pq5M18JDtviHnLEnRFcAoJXRj9mZUA0YKesFmy7XyJcCfvBt3NxOMW3XgSYeR57LQ05upjGmKcwrvkrxJq_56HyOqeoxOy74CmfkgfgcM3dE0QeXceA3oZB9QkeZezd7TDwF-v2UPRrdhvDZ6T5nvz5_urz4Wi2_f_l28XFZeaUhV0KpGqCpy9GykdLUzujWtSi1V72X3tcKOuO10noE7E3jemidUaqtxTh08py9PuZuU7zeIWU7BfK42bgZ446sEdIYBc29oOj2fXb7xJf_gVdxl-byCSs0lC217kyh9JHyKRIlHO02hcmlWyvA7rXZgza7d2JB2oM2K8vci1P6rp9wuJs6eSrAqxPgyLvNWLz4QHecrhsQhzU_HDks7f4JmCz5gKX_IST02Q4x3LPKX2fesa8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505365597</pqid></control><display><type>article</type><title>The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Krippl, Peter ; Langsenlehner, Uwe ; Renner, Wilfried ; Yazdani-Biuki, Babak ; Wolf, Gerald ; Wascher, Thomas C. ; Paulweber, Bernhard ; Bahadori, Babak ; Samonigg, Hellmut</creator><creatorcontrib>Krippl, Peter ; Langsenlehner, Uwe ; Renner, Wilfried ; Yazdani-Biuki, Babak ; Wolf, Gerald ; Wascher, Thomas C. ; Paulweber, Bernhard ; Bahadori, Babak ; Samonigg, Hellmut</creatorcontrib><description>Transforming growth factor-beta 1 (TGF-β1) is a potent inhibitor of proliferation of epithelial, endothelial and hematopoietic cells and acts as a tumor suppressor. The gene for TGF-β1, TGFB1, carries a common T/C variation of nucleotide 29, resulting in a leucine (L) to proline (P) polymorphism at codon 10 (TGFB1 L10P). The less common 10P allele has repeatedly been linked to higher TGF-β1 levels and in at least one study to a lower incidence of breast cancer. To further analyze the role of this polymorphism for breast cancer risk, 500 patients with histologically confirmed breast cancer and 500 sex-and age-matched healthy control subjects were genotyped for the TGFB1 L10P polymorphism by an allele-specific polymerase chain reaction assay. TGFB1 LL, LP and PP genotype frequencies were not significantly different for patients (39.6, 44.2, 16.2%) and controls (36.5, 45.9, 17.6%). We conclude that the TGFB1 L10P polymorphism is not associated with breast cancer risk.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/S0304-3835(03)00468-3</identifier><identifier>PMID: 14607332</identifier><identifier>CODEN: CALEDQ</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Age ; Age Distribution ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - genetics ; Case-Control Studies ; Confidence intervals ; DNA, Neoplasm - genetics ; Female ; Gene polymorphism ; Genotype ; Genotype & phenotype ; Hormone replacement therapy ; Humans ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Polymorphism, Genetic - genetics ; Risk Factors ; Transforming growth factor ; Transforming Growth Factor beta - genetics ; Transforming Growth Factor beta1 ; transforming growth factor-^b1 ; Tumors ; Women</subject><ispartof>Cancer letters, 2003-11, Vol.201 (2), p.181-184</ispartof><rights>2003 Elsevier Ireland Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Nov 25, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-144200620625363372a758a8e35c4bc3cc24097c5455f0eb76ab08a744821fd93</citedby><cites>FETCH-LOGICAL-c450t-144200620625363372a758a8e35c4bc3cc24097c5455f0eb76ab08a744821fd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383503004683$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15260199$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14607332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krippl, Peter</creatorcontrib><creatorcontrib>Langsenlehner, Uwe</creatorcontrib><creatorcontrib>Renner, Wilfried</creatorcontrib><creatorcontrib>Yazdani-Biuki, Babak</creatorcontrib><creatorcontrib>Wolf, Gerald</creatorcontrib><creatorcontrib>Wascher, Thomas C.</creatorcontrib><creatorcontrib>Paulweber, Bernhard</creatorcontrib><creatorcontrib>Bahadori, Babak</creatorcontrib><creatorcontrib>Samonigg, Hellmut</creatorcontrib><title>The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Transforming growth factor-beta 1 (TGF-β1) is a potent inhibitor of proliferation of epithelial, endothelial and hematopoietic cells and acts as a tumor suppressor. The gene for TGF-β1, TGFB1, carries a common T/C variation of nucleotide 29, resulting in a leucine (L) to proline (P) polymorphism at codon 10 (TGFB1 L10P). The less common 10P allele has repeatedly been linked to higher TGF-β1 levels and in at least one study to a lower incidence of breast cancer. To further analyze the role of this polymorphism for breast cancer risk, 500 patients with histologically confirmed breast cancer and 500 sex-and age-matched healthy control subjects were genotyped for the TGFB1 L10P polymorphism by an allele-specific polymerase chain reaction assay. TGFB1 LL, LP and PP genotype frequencies were not significantly different for patients (39.6, 44.2, 16.2%) and controls (36.5, 45.9, 17.6%). We conclude that the TGFB1 L10P polymorphism is not associated with breast cancer risk.</description><subject>Adult</subject><subject>Age</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Case-Control Studies</subject><subject>Confidence intervals</subject><subject>DNA, Neoplasm - genetics</subject><subject>Female</subject><subject>Gene polymorphism</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Risk Factors</subject><subject>Transforming growth factor</subject><subject>Transforming Growth Factor beta - genetics</subject><subject>Transforming Growth Factor beta1</subject><subject>transforming growth factor-^b1</subject><subject>Tumors</subject><subject>Women</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7rj6E5SAKHporXSSTvdJZPELBhRczyGdrp7JOt2ZTWVc9t-b-cAFLwuBHPLUS-V9GHsu4J0A0bz_CRJUJVup34B8C6CatpIP2EK0pq5M18JDtviHnLEnRFcAoJXRj9mZUA0YKesFmy7XyJcCfvBt3NxOMW3XgSYeR57LQ05upjGmKcwrvkrxJq_56HyOqeoxOy74CmfkgfgcM3dE0QeXceA3oZB9QkeZezd7TDwF-v2UPRrdhvDZ6T5nvz5_urz4Wi2_f_l28XFZeaUhV0KpGqCpy9GykdLUzujWtSi1V72X3tcKOuO10noE7E3jemidUaqtxTh08py9PuZuU7zeIWU7BfK42bgZ446sEdIYBc29oOj2fXb7xJf_gVdxl-byCSs0lC217kyh9JHyKRIlHO02hcmlWyvA7rXZgza7d2JB2oM2K8vci1P6rp9wuJs6eSrAqxPgyLvNWLz4QHecrhsQhzU_HDks7f4JmCz5gKX_IST02Q4x3LPKX2fesa8</recordid><startdate>20031125</startdate><enddate>20031125</enddate><creator>Krippl, Peter</creator><creator>Langsenlehner, Uwe</creator><creator>Renner, Wilfried</creator><creator>Yazdani-Biuki, Babak</creator><creator>Wolf, Gerald</creator><creator>Wascher, Thomas C.</creator><creator>Paulweber, Bernhard</creator><creator>Bahadori, Babak</creator><creator>Samonigg, Hellmut</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20031125</creationdate><title>The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk</title><author>Krippl, Peter ; Langsenlehner, Uwe ; Renner, Wilfried ; Yazdani-Biuki, Babak ; Wolf, Gerald ; Wascher, Thomas C. ; Paulweber, Bernhard ; Bahadori, Babak ; Samonigg, Hellmut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-144200620625363372a758a8e35c4bc3cc24097c5455f0eb76ab08a744821fd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Age</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Case-Control Studies</topic><topic>Confidence intervals</topic><topic>DNA, Neoplasm - genetics</topic><topic>Female</topic><topic>Gene polymorphism</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Risk Factors</topic><topic>Transforming growth factor</topic><topic>Transforming Growth Factor beta - genetics</topic><topic>Transforming Growth Factor beta1</topic><topic>transforming growth factor-^b1</topic><topic>Tumors</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krippl, Peter</creatorcontrib><creatorcontrib>Langsenlehner, Uwe</creatorcontrib><creatorcontrib>Renner, Wilfried</creatorcontrib><creatorcontrib>Yazdani-Biuki, Babak</creatorcontrib><creatorcontrib>Wolf, Gerald</creatorcontrib><creatorcontrib>Wascher, Thomas C.</creatorcontrib><creatorcontrib>Paulweber, Bernhard</creatorcontrib><creatorcontrib>Bahadori, Babak</creatorcontrib><creatorcontrib>Samonigg, Hellmut</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krippl, Peter</au><au>Langsenlehner, Uwe</au><au>Renner, Wilfried</au><au>Yazdani-Biuki, Babak</au><au>Wolf, Gerald</au><au>Wascher, Thomas C.</au><au>Paulweber, Bernhard</au><au>Bahadori, Babak</au><au>Samonigg, Hellmut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2003-11-25</date><risdate>2003</risdate><volume>201</volume><issue>2</issue><spage>181</spage><epage>184</epage><pages>181-184</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><coden>CALEDQ</coden><abstract>Transforming growth factor-beta 1 (TGF-β1) is a potent inhibitor of proliferation of epithelial, endothelial and hematopoietic cells and acts as a tumor suppressor. The gene for TGF-β1, TGFB1, carries a common T/C variation of nucleotide 29, resulting in a leucine (L) to proline (P) polymorphism at codon 10 (TGFB1 L10P). The less common 10P allele has repeatedly been linked to higher TGF-β1 levels and in at least one study to a lower incidence of breast cancer. To further analyze the role of this polymorphism for breast cancer risk, 500 patients with histologically confirmed breast cancer and 500 sex-and age-matched healthy control subjects were genotyped for the TGFB1 L10P polymorphism by an allele-specific polymerase chain reaction assay. TGFB1 LL, LP and PP genotype frequencies were not significantly different for patients (39.6, 44.2, 16.2%) and controls (36.5, 45.9, 17.6%). We conclude that the TGFB1 L10P polymorphism is not associated with breast cancer risk.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>14607332</pmid><doi>10.1016/S0304-3835(03)00468-3</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2003-11, Vol.201 (2), p.181-184 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71377406 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Age Age Distribution Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Breast cancer Breast Neoplasms - genetics Case-Control Studies Confidence intervals DNA, Neoplasm - genetics Female Gene polymorphism Genotype Genotype & phenotype Hormone replacement therapy Humans Medical sciences Middle Aged Pharmacology. Drug treatments Polymorphism, Genetic - genetics Risk Factors Transforming growth factor Transforming Growth Factor beta - genetics Transforming Growth Factor beta1 transforming growth factor-^b1 Tumors Women |
| title | The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A10%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20L10P%20polymorphism%20of%20the%20transforming%20growth%20factor-beta%201%20gene%20is%20not%20associated%20with%20breast%20cancer%20risk&rft.jtitle=Cancer%20letters&rft.au=Krippl,%20Peter&rft.date=2003-11-25&rft.volume=201&rft.issue=2&rft.spage=181&rft.epage=184&rft.pages=181-184&rft.issn=0304-3835&rft.eissn=1872-7980&rft.coden=CALEDQ&rft_id=info:doi/10.1016/S0304-3835(03)00468-3&rft_dat=%3Cproquest_cross%3E19187299%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505365597&rft_id=info:pmid/14607332&rft_els_id=S0304383503004683&rfr_iscdi=true |